EGFR and colorectal carcinoma: In a clinical setting, of CRC patients who responded to treatment with anti-EGFR Cetuximab and Panitumumab (among KRAS wild-type tumors, only 12–17% patients had durable responses to anti-EGFR monotherapy), invariably developing resistance within several months after initial response.